binimetinib,
MEK162,
Binimetinib,
606143-89-9,
MEK162,
ARRY-162,
MEK-162,
ARRY-438162,
5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide,
ARRY 162,
UNII-181R97MR71,
MEK162 (ARRY-162, ARRY-438162),
Binimetinib (MEK162, ARRY-162, ARRY-438162),
181R97MR71,
Binimetinib [USAN:INN],
Mektovi,
ARRY 438162,
ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162,
MEK162(Binimetinib),
Binimetinib (JAN/USAN),
NVP-MEK162,
MLS006011180,
C17H15BrF2N4O3,
SCHEMBL570088,
GTPL7921,
CHEMBL3187723,
MEK162 (Arry-162),
AOB2072,
DTXSID70209422,
QCR-138,
ACWZRVQXLIRSDF-UHFFFAOYSA-N,
ARRY-162,MEK-162,
HMS3652J14,
BCP06780,
EX-A1024,
MFCD22124525,
s7007,
ZINC38460704,
AKOS026750517,
CS-0627,
DB11967,
RL04283,
SB16501,
KS-0000062X,
NCGC00345804-01,
NCGC00345804-10,
6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide,
AC-29023,
AK175886,
AS-16706,
BC600594,
HY-15202,
SMR004702949,
cas:606143-89-9;MEK162,
AB0095018,
FT-0697088,
SW219910-1,
Y1468,
A11493,
D10604,
W-5894,
Binimetinib;MEK-162; ARRY-162;ARRY-438162,
J-516581,
5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide,
5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide,
5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami,
6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide,
6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide,
6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide,
D0C4LF,
cc-455,
AZD6244,
CID10288191,
CID 10288191,
A1947,
4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-,
651031-01-5,
1073666-70-2,